AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

 AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Shots:

  • Frontier to receive$55M up front and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products. The company might get ~45M within the first 12mos. of collaboration
  • Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of P-II
  • AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets

Click here ­to­ read full press release/ article | Ref: Abbvie | Image: Stat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post